BDX logo

BECTON DICKINSON AND CO

BDXNYSE
πŸ† #299 by market capEarnings Nov 5US Equity
$180.89β–Ό $2.89 (βˆ’1.60%)
Live
πŸ””
Track BDX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.6%
7dβ–Ό 1.3%
14dβ–Ό 2.7%
30dβ–Ό 4.6%
ytdβ–Ό 6.8%
1yβ–Ό 1.6%
🏦Market Cap
$49.84B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-2.6%
Declining
πŸ“ŠGross Margin
46.7%
Healthy
πŸ’΅FCF Margin
12.5%
Healthy
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$179.38 – $181.83
52-Week Range
$127.59 – $193.07
Volume
$4.56B
Avg Volume
$4.64B
Shares Outstanding
275.5M
Next Earnings
Nov 7, 2026

Fundamentals Snapshot

Annual Revenue
$21.84B
Last Q Revenue
$4.98B
P/E Ratio
52.9
P/S Ratio
2.4x
EPS (TTM)
$3.31
Dividend Yield
2.35%
Dilution (1yr)
βˆ’1.8%

Why Investors Own BDX

  • βœ“High-growth profile β€” revenue up +58.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BDX logo

BECTON DICKINSON AND CO

BDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$21.8Bβ–² +8.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
45.4%β–² +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.6Bβ–² +7.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.7Bβ–Ό βˆ’13.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
285.1Mβ–Ό βˆ’1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$18.5Bβ–Ό βˆ’$468M YoY
StockOtter Β· stockotter.space

About BECTON DICKINSON AND CO

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
84/100

Analyst Price Target

β“˜
Average Target
$235.55
β–² +30.2% Upside
High Target$296.72
Low Target$213.29
Based on 22 analysts

Latest News & Updates

24/7 Wall StreetΒ·7h ago

3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year.

PRNewsWireΒ·7h ago

BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy

Generations of Utah employees have helped ensure the reliable supply of essential medical devices that clinicians use every day to care for patients around the world SANDY, Utah, Sept. 29, 2026 /PRNewswire/ -- BD (Becton

🌌
Zacks Investment ResearchΒ·1d ago

Here's Why You Should Retain BDX Stock in Your Portfolio for Now

Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.

Seeking AlphaΒ·3d ago

Best Dividend Kings: September 2026

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of

Defense WorldΒ·4d ago

Engineers Gate Manager LP Buys New Shares in Becton, Dickinson and Company $BDX

Engineers Gate Manager LP purchased a new position in Becton, Dickinson and Company (NYSE: BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fu

PRNewsWireΒ·8d ago

Arthur Hu to Join BD as Chief Information and Digital Officer

FRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice preside